Construction and Validation of a Predictive Model for Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer Survivors Receiving Taxane-Based Chemotherapy: A Multicenter Cross-sectional Study.
Ruo-Lin Li, Jing Li, Jun-E Liu, Li-Xiao Bai, Juan Liu, Ci Li
{"title":"Construction and Validation of a Predictive Model for Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer Survivors Receiving Taxane-Based Chemotherapy: A Multicenter Cross-sectional Study.","authors":"Ruo-Lin Li, Jing Li, Jun-E Liu, Li-Xiao Bai, Juan Liu, Ci Li","doi":"10.1097/NCC.0000000000001516","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Breast cancer survivors (BCSs) undergoing taxane-based chemotherapy frequently experience chemotherapy-induced peripheral neuropathy (CIPN), potentially affecting their quality of life. Early identification of high-risk survivors can help mitigate the severity of CIPN.</p><p><strong>Objective: </strong>To construct and validate a predictive model for CIPN in BCSs receiving taxane-based chemotherapy.</p><p><strong>Methods: </strong>In this multicenter cross-sectional study conducted across 10 hospitals in China between April 2022 and March 2023, 569 BCSs were randomly assigned to development (n = 401) or validation (n = 168) sets (ratio, 7:3). Predictive factors were identified by multiple logistic regression, and a nomogram was constructed. Model discrimination was evaluated using receiver operating characteristic curves and area under the curve values, whereas calibration was assessed with the Hosmer-Lemeshow test and calibration curves. Decision curve analysis was performed to evaluate clinical utility.</p><p><strong>Results: </strong>CIPN was observed in 82.8% of the survivors. The nomogram included 5 factors: treatment with paclitaxel liposome, treatment with albumin-bound paclitaxel, number of chemotherapy cycles, vitamin D deficiency, and fatigue levels. The area under the curve values for the development and validation sets were 0.866 (95% confidence interval, 0.817-0.914) and 0.848 (95% confidence interval, 0.761-0.935), respectively, indicating good performance. The Hosmer-Lemeshow test and decision curve analysis confirmed good calibration and clinical utility.</p><p><strong>Conclusions: </strong>The nomogram model demonstrates good discrimination and calibration, offering a practical and visual tool for identifying high-risk survivors for CIPN.</p><p><strong>Implications for practice: </strong>This predictive model can assist clinicians in the early identification of BCSs at high risk for CIPN and in promptly implementing preventive measures.</p>","PeriodicalId":50713,"journal":{"name":"Cancer Nursing","volume":" ","pages":""},"PeriodicalIF":2.4000,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Nursing","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/NCC.0000000000001516","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"NURSING","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Breast cancer survivors (BCSs) undergoing taxane-based chemotherapy frequently experience chemotherapy-induced peripheral neuropathy (CIPN), potentially affecting their quality of life. Early identification of high-risk survivors can help mitigate the severity of CIPN.
Objective: To construct and validate a predictive model for CIPN in BCSs receiving taxane-based chemotherapy.
Methods: In this multicenter cross-sectional study conducted across 10 hospitals in China between April 2022 and March 2023, 569 BCSs were randomly assigned to development (n = 401) or validation (n = 168) sets (ratio, 7:3). Predictive factors were identified by multiple logistic regression, and a nomogram was constructed. Model discrimination was evaluated using receiver operating characteristic curves and area under the curve values, whereas calibration was assessed with the Hosmer-Lemeshow test and calibration curves. Decision curve analysis was performed to evaluate clinical utility.
Results: CIPN was observed in 82.8% of the survivors. The nomogram included 5 factors: treatment with paclitaxel liposome, treatment with albumin-bound paclitaxel, number of chemotherapy cycles, vitamin D deficiency, and fatigue levels. The area under the curve values for the development and validation sets were 0.866 (95% confidence interval, 0.817-0.914) and 0.848 (95% confidence interval, 0.761-0.935), respectively, indicating good performance. The Hosmer-Lemeshow test and decision curve analysis confirmed good calibration and clinical utility.
Conclusions: The nomogram model demonstrates good discrimination and calibration, offering a practical and visual tool for identifying high-risk survivors for CIPN.
Implications for practice: This predictive model can assist clinicians in the early identification of BCSs at high risk for CIPN and in promptly implementing preventive measures.
期刊介绍:
Each bimonthly issue of Cancer Nursing™ addresses the whole spectrum of problems arising in the care and support of cancer patients--prevention and early detection, geriatric and pediatric cancer nursing, medical and surgical oncology, ambulatory care, nutritional support, psychosocial aspects of cancer, patient responses to all treatment modalities, and specific nursing interventions. The journal offers unparalleled coverage of cancer care delivery practices worldwide, as well as groundbreaking research findings and their practical applications.